Shanghai Fosun Pharmaceutical's subsidiary has had its drug registration application for Decitabine accepted by the National Medical Products Administration for review.

Shanghai Fosun Pharmaceutical (02196) announced that its subsidiary, Fosun Pharma (Group) Co., Ltd. (hereinafter referred to as "the Company"), has had its drug registration application for the product known as Du Ruxolitinib Capsules (project code: SAF-189, application registration classification: Class 1 chemical drugs; hereinafter referred to as "the new drug") accepted by the National Medical Products Administration. The indication for this application is for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) patients who are positive for anaplastic lymphoma kinase (ALK).